These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30408225)

  • 1. High PTGS2 expression in post-neoadjuvant chemotherapy-treated oesophageal adenocarcinoma is associated with improved survival: a population-based cohort study.
    Spence AD; Trainor J; McMenamin Ú; Turkington RC; McQuaid S; Bingham V; James J; Salto-Tellez M; McManus DT; Johnston BT; Cardwell CR; Coleman HG
    Histopathology; 2019 Mar; 74(4):587-596. PubMed ID: 30408225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of surgery after prolonged primary chemotherapy for advanced oesophageal adenocarcinoma.
    Aboul-Enein MS; Knight W; Wulaningsih W; Foley DM; Dellaportas D; Zylstra J; Baker CR; Kelly M; Smyth E; Lagergren J; Maisey N; Allum WH; Gossage JA; Cunningham D; Davies AR;
    J Surg Oncol; 2021 Dec; 124(8):1296-1305. PubMed ID: 34403501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
    Kosumi K; Hamada T; Zhang S; Liu L; da Silva A; Koh H; Twombly TS; Mima K; Morikawa T; Song M; Nowak JA; Nishihara R; Saltz LB; Niedzwiecki D; Ou FS; Zemla T; Mayer RJ; Baba H; Ng K; Giannakis M; Zhang X; Wu K; Giovannucci EL; Chan AT; Fuchs CS; Meyerhardt JA; Ogino S
    Eur J Cancer; 2019 Apr; 111():82-93. PubMed ID: 30826660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis and autophagy markers predict survival in neoadjuvant treated oesophageal adenocarcinoma patients.
    El Mashed S; O'Donovan TR; Kay E; O'Grady A; McManus D; Turkington RC; McKenna SL
    BMC Cancer; 2022 Aug; 22(1):908. PubMed ID: 35986318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.
    Borg D; Larsson AH; Hedner C; Nodin B; Johnsson A; Jirström K
    J Transl Med; 2018 Oct; 16(1):290. PubMed ID: 30355278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.
    Fareed KR; Al-Attar A; Soomro IN; Kaye PV; Patel J; Lobo DN; Parsons SL; Madhusudan S
    Br J Cancer; 2010 May; 102(11):1600-7. PubMed ID: 20461087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.
    Bain GH; Collie-Duguid E; Murray GI; Gilbert FJ; Denison A; McKiddie F; Ahearn T; Fleming I; Leeds J; Phull P; Park K; Nanthakumaran S; Matula KM; Grabsch HI; Tan P; Welch A; Schweiger L; Dahle-Smith A; Urquhart G; Finegan M; Petty RD
    Br J Cancer; 2014 Mar; 110(6):1525-34. PubMed ID: 24569475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
    Shitara K; Rha SY; Wyrwicz LS; Oshima T; Karaseva N; Osipov M; Yasui H; Yabusaki H; Afanasyev S; Park YK; Al-Batran SE; Yoshikawa T; Yanez P; Dib Bartolomeo M; Lonardi S; Tabernero J; Van Cutsem E; Janjigian YY; Oh DY; Xu J; Fang X; Shih CS; Bhagia P; Bang YJ;
    Lancet Oncol; 2024 Feb; 25(2):212-224. PubMed ID: 38134948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.
    Hamy AS; Tury S; Wang X; Gao J; Pierga JY; Giacchetti S; Brain E; Pistilli B; Marty M; Espié M; Benchimol G; Laas E; Laé M; Asselain B; Aouchiche B; Edelman M; Reyal F
    J Clin Oncol; 2019 Mar; 37(8):624-635. PubMed ID: 30702971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.
    Sundar R; Ng A; Zouridis H; Padmanabhan N; Sheng T; Zhang S; Lee MH; Ooi WF; Qamra A; Inam I; Hewitt LC; So JB; Koh V; Nankivell MG; Langley RE; Allum WH; Cunningham D; Rozen SG; Yong WP; Grabsch HI; Tan P
    Eur J Cancer; 2019 Dec; 123():48-57. PubMed ID: 31655359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
    Moore JL; Subesinghe M; Santaolalla A; Green M; Deere H; Van Hemelrijck M; Lagergren J; Chicklore S; Maisey N; Gossage JA; Kelly M; Baker CR; Davies AR;
    Eur Radiol; 2023 May; 33(5):3647-3659. PubMed ID: 36920518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma.
    Vos EL; Carr RA; Hsu M; Nakauchi M; Nobel T; Russo A; Barbetta A; Tan KS; Tang L; Ilson D; Ku GY; Wu AJ; Janjigian YY; Yoon SS; Bains MS; Jones DR; Coit D; Molena D; Strong VE
    Br J Surg; 2021 Nov; 108(11):1332-1340. PubMed ID: 34476473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma.
    Reece-Smith AM; Saunders JH; Soomro IN; Bowman CR; Duffy JP; Kaye PV; Welch NT; Madhusudan S; Parsons SL
    Ann R Coll Surg Engl; 2017 May; 99(5):378-384. PubMed ID: 28462649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
    J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma.
    Powell AGMT; Chin C; Coxon AH; Chalishazar A; Christian A; Roberts SA; Lewis WG
    BJS Open; 2020 Jun; 4(3):416-423. PubMed ID: 32232963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.
    Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
    J Clin Pathol; 2018 May; 71(5):451-462. PubMed ID: 29138285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy.
    Powell AGMT; Karran A; Blake P; Christian A; Roberts SA; Lewis WG
    BJS Open; 2020 Aug; 4(4):593-600. PubMed ID: 32374504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of a positive circumferential resection margin at surgery following neoadjuvant chemotherapy for adenocarcinoma of the oesophagus.
    Knight WRC; Yip C; Wulaningsih W; Jacques A; Griffin N; Zylstra J; Van Hemelrijck M; Maisey N; Gaya A; Baker CR; Kelly M; Gossage JA; Lagergren J; Landau D; Goh V; Davies AR; ; Ngan S; Qureshi A; Deere H; Green M; Chang F; Mahadeva U; Gill-Barman B; George S; Dunn J; Zeki S; Meenan J; Hynes O; Tham G; Iezzi C
    BJS Open; 2019 Dec; 3(6):767-776. PubMed ID: 31832583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D receptor as a marker of prognosis in oesophageal adenocarcinoma: a prospective cohort study.
    McCain S; Trainor J; McManus DT; McMenamin ÚC; McQuaid S; Bingham V; James JA; Salto-Tellez M; Turkington RC; Coleman HG
    Oncotarget; 2018 Sep; 9(76):34347-34356. PubMed ID: 30344947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.